Catabasis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Astria Therapeutics

09/08/2021 22:19

* Catabasis Pharmaceuticals Inc  CATB.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 30 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Catabasis Pharmaceuticals Inc's reported EPS for the quarter
was a loss of 89 cents​.
* The mean earnings estimate of analysts had fallen by
about 83.8% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Catabasis Pharmaceuticals Inc shares had fallen by 26.5% this
quarter and lost 27.6% so far this year.
* The company reported a quarterly loss of $31.9 million.
* Wall Street's median 12-month price target for Catabasis
Pharmaceuticals Inc is $5.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 9 at 09:18 p.m.  ​All
figures in US dollars unless otherwise stated